| |
|
|
| |
|
|
| |
HUM-MOLGEN
-> Events
-> Courses and Workshops |
|
|
| |
Three Key Aspects of Risk Management during Phase 3 Clinical Trials | |
| |
March 17, 2008 |
|
|
| |
|
|
| |
|
|
|
Drug Information Association, Online
Apr 23 2008
Risk Minimization Action Plans (Risk MAPs) evolve as clinical and safety data emerge in a product’s lifecycle. Risk MAPs should begin to be developed as early in the product life cycle as possible, prior to an NDA filing. The phase 3 time period offers an opportunity to inform a post-marketing risk minimization program. This webinar will teach you how to:·Incorporate a Risk MAP within a pre-marketing clinical trial;·Evaluate clinical trial data as a basis for developing a RiskMAP strategy; and·Use the phase 3 program to test and refine Risk MAP tools.
|
|
|
|
|
|
|
|
Organized by:
|
|
Drug Information Association |
|
|
Invited Speakers:
|
|
Annette Stemhagen, Dr PH, FISPE.Vice President, Epidemiology and Risk ManagementUnited Biosource CorporationUnited States.
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
-
|
|
|
|
|
|
|
|
Registration:
|
|
http://www.diahome.org/DIAHOME/Education/FindEducationalOffering.aspx?productID=16994&eventType=Webinar
|
|
|
E-mail:
|
|
dia@diahome.org
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp,
Frank S.
Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved.
Liability, Copyright and Imprint. |
|